Dr. Hamilton is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
23 Pocono Rd
Denville, NJ 07834Phone+1 646-227-3813Fax+1 908-542-3220
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 1991 - 1994
Brigham and Women's HospitalResidency, Internal Medicine, 1983 - 1986
Harvard Medical SchoolClass of 1983
Certifications & Licensure
NJ State Medical License 1996 - 2025
NY State Medical License 1985 - 2024- American Board of Internal Medicine Internal Medicine
Awards, Honors, & Recognition
- Inside Jersey Top Doctors for Cancer Castle Connolly, 2012-2014
- Inside Jersey Magazine Top Doctors Castle Connolly, 2010-2014
- Top Doctors: New York Metro Area Castle Connolly, 2005, 2009-2014
- Join now to see all
Publications & Presentations
PubMed
- 91 citationsFollicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroupsConnie Lee Batlevi, Fushen Sha, Anna Alperovich, Ai Ni, Katy Smith
Blood Cancer Journal. 2020-07-17 - 864 citationsCetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by ImmunohistochemistryKi Y. Chung, Jinru Shia, Nancy E. Kemeny, Manish A. Shah, Gary K. Schwartz
Journal of Clinical Oncology. 2005-03-20 - 86 citationsPhase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma.Alison J. Moskowitz, Gunjan L. Shah, Heiko Schöder, Nivetha Ganesan, Esther Drill
Journal of Clinical Oncology. 2021-06-25
Abstracts/Posters
- High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed ...Audrey Hamilton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin LymphomaAudrey Hamilton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin LymphomaAudrey Hamilton, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
